Hematology drug pipeline

Sickle cell, haemophilia, thrombosis, transfusion medicine, and other blood-related therapeutics.

Recent approvals (last 30 days)

No approvals in this window.

Upcoming PDUFA dates (next 6 months)

No upcoming decisions in this window.

Top sponsors

1. · 102 drugs
2. Pfizer · 13 drugs
3. Baxalta now part of Shire · 11 drugs
4. Bayer · 9 drugs
5. CSL Behring · 9 drugs
6. Amgen · 9 drugs
7. GlaxoSmithKline · 9 drugs
8. Hoffmann-La Roche · 7 drugs
9. Peking Union Medical College Hospital · 7 drugs
10. Assistance Publique - Hôpitaux de Paris · 7 drugs

Key drug classes

• Erythropoiesis-stimulating agent (ESA) · 36
• Iron supplement · 23
• Antifibrinolytic agent · 20
• Iron replacement agent · 18
• Thrombopoietin receptor agonist · 15
• Iron replacement therapy · 10
• Recombinant coagulation factor VIII · 7
• Blood product / Plasma derivative · 7
• Iron chelator · 7
• Intravenous iron replacement agent · 7
• Ribonucleotide reductase inhibitor · 6
• Vitamin C [EPC] · 6
• Recombinant clotting factor · 6
• Recombinant coagulation factor · 6
• Coagulation factor replacement therapy · 5

Subscribe

Get hematology approvals + PDUFA dates in your RSS reader:

• Hematology RSS feed · Atom · JSON

Other therapeutic areas